Research
Hormonal
Tirzepatide 15mg is associated with a higher rate of adverse events compared to other GLP-1RAs, although not significantly different from placebo in some metrics, it ranks highest in SUCRA for adverse events.
Tirzepatide 15mg is highly effective but comes with a higher risk of side effects like nausea and diarrhea compared to other GLP-1s. Patients should be prepared for this and work with their doctor on dose titration to manage it.
StrongQualifiesHIGH confidence
Tirzepatide 15mg had the highest incidence of adverse events compared to all other interventions.
Why this rating
Network meta-analysis of 34 RCTs.
Source
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Zeyu Xie et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1244432
Meta-analysis · 34 studiesCited 43×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →